Overview

A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of AB801 in Healthy Volunteers

Status:
Completed
Trial end date:
2024-02-15
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to determine the safety and tolerability of AB801, and to understand the pharmacokinetic (PK) profile of AB801 when taken as a capsule and tablet in healthy volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
Arcus Biosciences, Inc.